BidTerrierSign in

Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

Health and Human Services, Department of, National Institutes of Health

9 days leftSources soughtMedical supplies and equipment
View the official notice at sam.gov

The official notice is always free. Read the full documents there before you bid.

Key facts

Closes
Nov 30, 2026, 11:00 AM ET (9 days left)
Place of work
Bethesda, Maryland
Notice type
Sources soughtThe agency is checking which businesses could do the work. It is not a request for a bid.
Solicitation number
75N98027R00020
Office
NATIONAL INSTITUTES OF HEALTH NIDA
Posted
Nov 16, 2026
Codes
NAICS 325411 | PSC AN11
Contact in the notice
Polina Klimenkova, polina.klimenkova@nih.gov
Source
SAM.gov Contract Opportunities

What this is

A plain-English summary has not been written for this notice yet. The facts above come straight from the notice, and the original description is further down this page.

Similar open bids

More medical supplies and equipment bids

Recent awards from Health and Human Services, Department of

Award notices this agency published, as listed by the source.

Original description from the notice

Title: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. Background: The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline. Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development. The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers. TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. Please see the attachment for more details.

Source: SAM.gov, General Services Administration (public domain). BidTerrier shows public notices as published and cannot confirm that a notice is complete or current. Details can change, so always check the official notice. Nothing here says whether your business is eligible.